101 not yet recruiting. 101 Phase 2, 30 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 101 | Not yet recruiting 101 |
| Phase 1 | 30 | Not yet recruiting 30 |
| Phase 3 | 2 | Not yet recruiting 2 |
Follow Neuroectodermal Tumors: new trials by email Literature Review of Neuroectodermal Tumors trials Research Report on Neuroectodermal Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma JBI-778 - Brain Metastases From Solid Tumors, Leptomeningeal Disease | Phase 1 / Phase 2 | Not yet recruiting | Jubilant Therapeutics Inc. | 113 | 2028-04-01 | 2026-08-07 |
| Combination Immunotherapy Targeting Melanoma Antigen-specific CAR T, CTL and DCvac to treat melanoma. - Melanoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-10-30 |
| H3K27M-specific Immune Effector Cells Targeting DMG/DIPG H3K27M-EIEs - Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-10-30 |
| Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG) ADI-PEG 20 (Arginine deiminase pegylated), Temozolomide (TMZ), Standard of Care Radiation Therapy (RT) - Glioblastoma, High-Grade Glioma (WHO III-IV) | Phase 1 / Phase 2 | Not yet recruiting | Sabine Mueller, MD, PhD | 97 | 2027-06-01 | 2026-09-15 |
| DLL3 CAR-T Therapy Targeting Brain Tumors 4SCAR DLL3 T cells - Glioblastoma of Cerebellum | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-01 | 2026-09-01 |
| Trial of Temozolomide in BAP1 Mutated Patients With Advanced or Metastatic Cutaneous Melanoma Temozolomide (TMZ) - Cutaneous Melanoma | Phase 2 | Not yet recruiting | Assistance Publique Hopitaux De Marseille | 28 | 2027-06-01 | 2026-09-08 |
| Metronomic Temozolomide With Dexbrompheniramine for Recurrent High-Grade Glioma/Glioblastoma Dexbrompheniramine, Temozolomide - High Grade Glioma, Glioblastoma | Phase 1 / Phase 2 | Not yet recruiting | University of Nebraska | 41 | 2027-06-01 | 2026-10-05 |
| Enfortumab Vedotin for the Treatment of Unresectable or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, or NUT Carcinoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Differentiated Thyroid Gland Carcinoma, Metastatic NUT Carcinoma | Phase 2 | Not yet recruiting | Northwestern University | 56 | 2027-05-05 | 2026-10-07 |
| Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma Cerebraca wafer, Temozolomide (for relapsed malignant glioma) - Recurrent Glioblastoma, IDH-Wildtype | Phase 2 / Phase 3 | Not yet recruiting | Everfront Biotech Co., Ltd. | 175 | 2027-04-01 | 2026-09-10 |
| Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy - Malignant Melanoma With Metastasis, Malignant Melanoma | Phase 2 | Not yet recruiting | Rapa Therapeutics LLC | 65 | 2027-03-01 | 2026-03-19 |
| Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG Opdualag - High Grade Glioma, Diffuse Intrinsic Pontine Glioma | Phase 2 | Not yet recruiting | Nationwide Children's Hospital | 12 | 2027-03-01 | 2026-09-09 |
| Safusidenib for Patients With Newly Diagnosed IDH1-mutant CNS WHO Grade 3 Oligodendroglioma and Astrocytoma - a Single Arm Phase II Study Safusidenib - Glioma : Oligodendroglioma or Astrocytoma | Phase 2 | Not yet recruiting | University of Zurich | 20 | 2027-03-01 | 2026-09-21 |
| STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL) Ivonescimab - Adrenocortical Carcinoma, Pheochromocytoma | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 20 | 2027-02-07 | 2026-09-18 |
| Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG) Tovorafenib - High Grade Glioma (HGG) of the Brain With BRAF Aberration, High Grade Glioma (III or IV) | Phase 2 | Not yet recruiting | Nationwide Children's Hospital | 79 | 2027-02-01 | 2026-10-20 |
| IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas IDH1-vac, IS-vac, Temozolomide (TMZ) - Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4 | Phase 2 | Not yet recruiting | German Cancer Research Center | 216 | 2027-02-01 | 2026-10-22 |
| Zanzalintinib in Unresectable and Progressive MPGGs Zanzalintinib - Pheochromocytoma, Paraganglioma | Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 14 | 2027-01-09 | 2026-07-20 |
| Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children, Adolescents and Young Adults Mirdametinib - LGCMN, Large and Giant Congenital Melanocytic Nevi | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 15 | 2027-01-04 | 2026-10-29 |
| NG101m Adjuvant Therapy in Glioblastoma Patients Intensity-modulated radiation therapy, Temozolomide, NG101m - Glioblastoma Multiforme | Phase 1 / Phase 2 | Not yet recruiting | NeuGATE Theranostics | 52 | 2027-01-01 | 2025-10-21 |
| Disulfiram/Copper Combination In The Treatment of Newly Diagnosed Glioblastoma Multiform Temozolomide, Disulfiram, Copper - Glioblastoma Multiforme | Phase 2 | Not yet recruiting | Olympion Medical Center | 32 | 2027-01-01 | 2025-05-25 |
| Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma mirdametinib with radiation, mirdametinib - Neurofibromatosis 1 (NF1) | Phase 2 | Not yet recruiting | University of Alabama at Birmingham | 55 | 2027-01-01 | 2026-10-05 |
Showing 20 of 101. Sign in to see all of them.
Glioblastoma (31) · Melanoma (30) · Glioma (16) · Ependymoma (6) · Astrocytoma (5) · Carcinoma, Neuroendocrine (5) · Neuroblastoma (5) · Brain Neoplasms (4) · Carcinoma, Renal Cell (4) · Colorectal Neoplasms (4) · Diffuse Intrinsic Pontine Glioma (4) · Lung Neoplasms (4) · Neoplasm Metastasis (4) · Neurofibromatosis 2 (4) · Recurrence (4)
Neoplasms by Histologic Type (101) · Neoplasms, Germ Cell and Embryonal (101) · Neoplasms, Nerve Tissue (101) · Neoplasms (98) · Neoplasms, Glandular and Epithelial (69) · Neoplasms, Neuroepithelial (53) · Neuroendocrine Tumors (48) · Neoplasms by Site (47) · Nevi and Melanomas (33) · Glioma (31) · Skin Diseases (30) · Skin Neoplasms (30) · Skin and Connective Tissue Diseases (30) · Astrocytoma (28)
Temozolomide (20) · Radiotherapy (5) · Cisplatin (4) · cemiplimab (4) · Bevacizumab (3) · Cyclophosphamide (3) · Ipilimumab (3) · Magnetic Resonance Spectroscopy (3) · Specimen Handling (3) · anlotinib (3) · pembrolizumab (3) · AZD 6244 (2) · Dexamethasone (2) · Etoposide (2) · Irinotecan (2)
Beijing Tiantan Hospital (4) · Shenzhen Geno-Immune Medical Institute (4) · M.D. Anderson Cancer Center (3) · Assistance Publique Hopitaux De Marseille (2) · Henan Provincial People's Hospital (2) · Nationwide Children's Hospital (2) · Regeneron Pharmaceuticals (2) · Shanghai Zhongshan Hospital (2) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (2) · University College, London (2) · University of California, Irvine (2) · University of Zurich (2) · Advenchen Pharmaceuticals, LLC. (1) · Amsterdam UMC, location VUmc (1) · Armando Santoro, MD (1)
United States (25) · China (21) · France (4) · Germany (2) · Italy (2) · Switzerland (2) · Australia (1) · Canada (1) · Greece (1) · Israel (1) · Uganda (1) · United Kingdom (1)
Ben Carnley, MBBS (1) · Carlen Yuen, MD (1) · Carlos K Matsuoka, MD (1) · Csaba Juhasz, M.D.,Ph.D. (1) · Daniel Fowler, M.D. (1) · Diana Hanna (1) · Girish Dhall, MD (1) · Guannan Zhu, M.D.;Ph.D (1) · Ido Didi Fabian, Prof. (1) · Isabelle T Seemann, Ph.D (1) · Jianpei Fang (1)
PMID 24344045, PMID 31917762, PMID 37249604, PMID 39105794, PMID 39422764, PMID 39952598, PMID 40501309
2025 (3), P30CA014089 (1), P30CA060553 (1)